The mechanism by which combination dosing of trastuzumab RP and pertuzumab results in increased efficacy with no demonstrated impact on safety is through binding to distinct epitopes on the HER2 extracellular domain which results in a synergistic effect on the inhibition and survival of breast cancer cells [7, 8, 20, 21]. Here, ERBB2 is linked to breast carcinoma.